It seems there was an error, as the content you provided is marked as "undefined." Please provide specific content for summarization.
AZN has been in the news recently: AstraZeneca PLC's stock increased by 4% after its drug tozorakimab demonstrated effectiveness in reducing flare-ups of chronic obstructive pulmonary disease (COPD) during late-stage clinical trials. Tozorakimab is a monoclonal antibody that targets IL-33 to help alleviate inflammation and mucus issues associated with COPD.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.